Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation oncology therapies for patients with high unmet medical needs. Founded by the former leadership team of Turning Point Therapeutics, the company focuses on targeting cell cycle regulators and advancing a robust pipeline of antibody-drug conjugates (ADCs) and small molecule inhibitors. The company leverages a precision medicine approach to identify and develop candidates that can overcome resistance mechanisms in solid tumors. Their strategy includes both internal R&D and strategic in-licensing of potentially best-in-class assets from global partners.